Q-omics provides the consensus-scored KCTD18 profile across patient tissues and cancer cell-line models. KCTD18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD18 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KCTD18 RNA expression shows 20,757 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where KCTD18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD18 survival associations across molecular data types. KCTD18 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD18 RNA expression–survival associations across cancer types. High KCTD18 expression shows unfavorable associations in KIRP and ACC, but favorable associations in KIRC, SKCM, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD18 RNA expression.
This table summarizes KCTD18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD18 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher KCTD18 RNA expression in tumor versus normal tissue (log2 FC = +0.437, t-test p < 0.001).
This table shows molecular features associated with KCTD18 in patient tissues and cancer cell lines. In patient samples, KCTD18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
